Chinese Biotech Overtakes AI as Emerging-Market Growth Trade
THE SO WHAT
Capital in emerging markets is rotating from AI to Chinese biotech, which means some AI valuations and funding assumptions in those regions are now on a shorter leash. If you’re building AI in or with exposure to EM, expect tougher terms and more scrutiny on real unit economics—not just model narratives.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureEuropean SpaceX Rival in Talks to Raise $300 Million, FT Reports
A $300M raise at a $2B+ valuation for The Exploration Company — with EU Scaleup Europe Fund participation — shows Europe is willing to underwrite its own launch and space logistics stack. Space-dependent operators should start modeling a world with more regional launch options and less single-vendor exposure.
Startups & VentureInside one London founder house rewriting the founder-house rules
The founder-house model is shifting from blitzscale cosplay to burnout mitigation — this is a bet that sustainable cadence is now a competitive edge in early-stage execution. Worth monitoring if you hire or back very young teams: expectations around work–life tradeoffs are quietly resetting.
Startups & VentureMost accelerators make atartups worse. What do the good ones do?
If NYU Stern’s work is right and most accelerators don’t improve outcomes, the default “join a program” playbook is now suspect. Founders should evaluate accelerators like any other vendor — specific capabilities, post-program leverage, and alumni traction — not as a generic de-risking move.
Startups & VentureDeepSeek pauses its second fundraising round after founder’s leaked investor comments go viral
A paused DeepSeek round after leaked investor comments is a reminder that founder-market narratives are now globally memetic in hours, not months. If you’re raising into a hot category, assume every private remark can become part of your regulatory, customer, and talent brand surface.